News Releases

Keyword Search

Jun-30-2020
Oncternal Therapeutics Announces Increased Focus of the Cirmtuzumab ROR1 Antibody Program on Mantle Cell Lymphoma
May-20-2020
Oncternal Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
May-19-2020
Oncternal Therapeutics Announces Presentation of Update on Phase 1/2 Clinical Trial of Cirmtuzumab in Combination with Ibrutinib at 2020 ASCO Annual Meeting
May-07-2020
Oncternal Provides Business Update and Announces First Quarter 2020 Financial Results
May-01-2020
Oncternal Therapeutics to Report First Quarter 2020 Financial Results and Provide Business Update
Mar-16-2020
Oncternal Provides Business Update and Announces Fourth Quarter and Full Year 2019 Financial Results
Mar-11-2020
Oncternal Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results and Provide Business Update
Mar-11-2020
Oncternal Therapeutics Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma
Feb-06-2020
Oncternal Therapeutics Announces Presentation of ROR1 CAR-T Preclinical Data at 2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Dec-12-2019
Oncternal Therapeutics Announces Presentation of Interim Clinical Data on Cirmtuzumab in Combination with Paclitaxel at 2019 San Antonio Breast Cancer Symposium